Biomarkers Consortium

Young research scientists

Spotlight

Lawrence Schwartz

The FNIH Biomarkers Consortium has launched a project, under its Neuroscience Steering Committee, with the potential to improve diagnosis and the development of targeted therapies for Alzheimer’s Disease (AD) and Major Depressive Disorder (MDD).

Inflammatory Markers

The FNIH Biomarkers Consortium has launched a project, under its Neuroscience Steering Committee, with the potential to improve diagnosis and the development of targeted therapies for Alzheimer’s Disease (AD) and Major Depressive Disorder (MDD).

habp/vabp

The FNIH Biomarkers Consortium has met a critical milestone that could improve clinical trials and accelerate treatment approvals for hospital-acquired bacterial infections.

The Biomarkers Consortium is a public-private biomedical research partnership managed by the Foundation for the National Institutes of Health that endeavors to discover, develop, and seek regulatory approval for biological markers (biomarkers) to support new drug development, preventive medicine, and medical diagnostics.

The Biomarkers Consortium is helping create a new era of precision medicine, with more highly predictive markers that have an impact during a patient’s illness or lifespan. Our goal is to combine the forces of the public and private sectors to accelerate the development of biomarker-based technologies, medicines, and therapies for the prevention, early detection, diagnosis, and treatment of disease.

Front Page: